Dr. Xinglei Shen
Claim this profileUniversity of Kansas Cancer Center
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
9 reported clinical trials
30 drugs studied
Area of expertise
1Prostate Cancer
Stage I
Stage II
Stage IV
2Prostate Adenocarcinoma
Affiliated Hospitals
Clinical Trials Xinglei Shen is currently running
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting2 awards Phase 3
More about Xinglei Shen
Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Xinglei Shen has experience with
- Radiation Therapy
- Bicalutamide
- Relugolix
- Apalutamide
- Histrelin
- Leuprolide
Breakdown of trials Xinglei Shen has run
Prostate Cancer
Prostate Adenocarcinoma
Bladder Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Xinglei Shen specialize in?
Xinglei Shen focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved Stage I patients, or patients who are Stage II.
Is Xinglei Shen currently recruiting for clinical trials?
Yes, Xinglei Shen is currently recruiting for 3 clinical trials in Kansas City Kansas. If you're interested in participating, you should apply.
Are there any treatments that Xinglei Shen has studied deeply?
Yes, Xinglei Shen has studied treatments such as Radiation Therapy, Bicalutamide, Relugolix.
What is the best way to schedule an appointment with Xinglei Shen?
Apply for one of the trials that Xinglei Shen is conducting.
What is the office address of Xinglei Shen?
The office of Xinglei Shen is located at: University of Kansas Cancer Center, Kansas City, Kansas 66160 United States. This is the address for their practice at the University of Kansas Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.